Biocardia awarded new u.s. patent covering helix system for local biotherapeutic delivery of autologous and allogenic cells to the heart

San carlos, calif., april 28, 2020 (globe newswire) -- biocardia®, inc., (otc: bcda), a leader in the development of comprehensive solutions for cardiovascular regenerative therapies, today announced the issuance of united states patent no. 10,632,281, entitled “drug delivery catheters that attach to tissue and methods for their use.” this new patent provides additional, broad protection for the helix™ biotherapeutic delivery system and covers the use of the helical needle delivery system with a deflectable guide catheter. the u.s. patent office has extended the life of this patent for 2.8 years beyond the usual 20-year term.
BCDA Ratings Summary
BCDA Quant Ranking